Background: Dexamethasone (DEX) is widely adopted to reduce tumor-associated edema in glioblastoma (GBM) patients despite its side effects
Current ideas and concerns about Dex's effects on GBM cerebral edema, cell proliferation, migration, and its clinical outcomes were investigated in this study
For asymptomatic patients, steroids are not required, however
Background: Dexamethasone (DEX) is widely adopted to reduce tumor-associated edema in glioblastoma (GBM) patients despite its side effects
A number of
Dexamethasone use was associated with shorter survival in a glioblastoma animal model and in a cohort of patients with glioblastoma treated with programmed cell
A disease-relevant mouse model of glioblastoma was used to characterize the effects of dexamethasone on tumour cell proliferation and death, and to identify
Corticosteroids are usually indicated in any patient with a malignant brain tumor and symptomatic peritumoral edema
The contradictions of dexamethasone for glioblastoma and brain metastasis therapy are discussed in this article
Despite radiation, chemotherapy, and radical surgery, the median survival of afflicted individuals is about 12 months
Methods: In this single-center retrospective cohort analysis, we electronically retrieved inpatient administration and outpatient prescriptions of dexamethasone and
This doesn’t help to treat the tumour itself, but might help with its symptoms or side effects
Keywords: Compliance; Dexamethasone; Glioblastoma; Meta-analysis; TTFields
You would normally start on a high dose of dexamethasone, which is then reduced to a level where your symptoms remain controlled
The guideline makes no mention of treatment for pediatric patients with brain tumor
Background: Dexamethasone (DEX) is widely adopted to reduce tumor-associated edema in glioblastoma (GBM) patients despite its side effects
The steroid Dex has been extensively used to treat GBM-induced brain edema and inflammation for many years (Dixit and Kumthekar, 2020)
1
Cerebral edema ( fluid build-up in the brain) associated with brain tumors
Patients with glioblastoma (GBM) exhibit profound systemic immune defects that affect the success of conventional and immune-based treatments
97; 3 studies; I 2: 71